`CORPORATION, (“WEST”) BUSINESS WIRE ARTICLES ON WESTLAWNEXT
`
`I swear that
`
`1. My name is Jennifer Rock and I have been employed by West Publishing Corporation in the
`area which acquires news articles for inclusion on Westlaw for 14 years.
`
`2. The following information is based on my knowledge of West’s customary and routine
`business practices during the time I have been employed.
`
`3. West obtains news articles under license from Business Wire for inclusion on Westlaw to
`permit authorized subscribers to access these articles.
`
`4. West includes the text of the news articles on Westlaw as they are received from Business
`Wire.
`
`5. The three articles attached to this affidavit are accurate copies of the articles as they appear
`on Westlaw as of today’s date.
`
`6. These three articles, to the best of my knowledge and belief, would have been available to
`authorized Westlaw subscribers as of the following times:
`
`a. Business Wire article titled “BG-12 Psoriasis Study Meets Primary Endpoint; Oral
`Compound Also Being Studied for MS in Phase II Trial” was available on April 7,
`2005 at 07:15:03 a.m. CT.
`b. Business Wire article titled “Phase II Study of Oral Compound BG-12 Meets Primary
`Endpoint in Multiple Sclerosis” was available on January 9, 2006 at 07:49:24 a.m.
`CT.
`c. Business Wire article titled “Oral Compound BG-12 Achieves Primary Endpoint in
`Phase II Study of Relapsing-Remitting Multiple Sclerosis; Treatment with BG-12
`Led to Statistically Significant Reductions in MRI measures” was available on May
`30, 2006 at 09:13:05 a.m. CT.
`
`I affirm that the statements contained herein are known by me or believed by me to be true and
`correct.
`
`2/20/2019
`
`X Jennifer Rock
`
`Jennifer Rock
`
`Signed by: U0067718
`
`Sworn by Jennifer Rock, West Publishing Corporation, 610 Opperman Drive, Eagan, MN 55123
`
`Sensitivity: Confidential
`
`Sawai (IPR2019-00789), Ex. 1059, p. 001
`
`
`
`
`
`
`
`
`
`
`
`
`Sensitivity: Confidential
`
`Sawai (IPR2019-00789), Ex. 1059, p. 002
`
`